JP2018537501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537501A5 JP2018537501A5 JP2018531479A JP2018531479A JP2018537501A5 JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5 JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound according
- ring
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019843A JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268765P | 2015-12-17 | 2015-12-17 | |
| US62/268,765 | 2015-12-17 | ||
| US201662353603P | 2016-06-23 | 2016-06-23 | |
| US62/353,603 | 2016-06-23 | ||
| PCT/US2016/067112 WO2017106607A1 (en) | 2015-12-17 | 2016-12-16 | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Division JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537501A JP2018537501A (ja) | 2018-12-20 |
| JP2018537501A5 true JP2018537501A5 (2) | 2020-01-30 |
| JP6882299B2 JP6882299B2 (ja) | 2021-06-02 |
Family
ID=58191545
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531479A Active JP6882299B2 (ja) | 2015-12-17 | 2016-12-16 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Active JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A Pending JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Active JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A Pending JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10399957B2 (2) |
| EP (3) | EP3889146A1 (2) |
| JP (4) | JP6882299B2 (2) |
| KR (2) | KR20250043596A (2) |
| CN (2) | CN113603675A (2) |
| AU (4) | AU2016371014B2 (2) |
| CA (1) | CA3005766A1 (2) |
| CL (1) | CL2018001624A1 (2) |
| DK (1) | DK3889145T3 (2) |
| ES (2) | ES2883285T3 (2) |
| FI (1) | FI3889145T3 (2) |
| HR (1) | HRP20240355T1 (2) |
| HU (1) | HUE066591T2 (2) |
| IL (4) | IL279751B (2) |
| LT (1) | LT3889145T (2) |
| MX (2) | MX385424B (2) |
| MY (2) | MY210123A (2) |
| NZ (1) | NZ742476A (2) |
| PH (1) | PH12018501068A1 (2) |
| PL (1) | PL3889145T3 (2) |
| PT (1) | PT3889145T (2) |
| RS (1) | RS65319B1 (2) |
| SG (2) | SG10202001146PA (2) |
| SI (1) | SI3889145T1 (2) |
| SM (1) | SMT202400141T1 (2) |
| TW (4) | TWI886474B (2) |
| UA (1) | UA124802C2 (2) |
| WO (1) | WO2017106607A1 (2) |
| ZA (1) | ZA201803367B (2) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| EP4198031A1 (en) * | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| ES2965044T3 (es) * | 2017-07-18 | 2024-04-10 | Merck Patent Gmbh | Antagonistas de TLR7/8 y sus usos |
| CN111542515B (zh) * | 2017-10-30 | 2023-12-05 | 科罗拉多州立大学董事会法人团体 | Toll样受体8(tlr8)特异性拮抗剂及其制备方法和用途 |
| CN111511729A (zh) * | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| KR20210018818A (ko) | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112585139B (zh) | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| AU2019297362B2 (en) * | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US20220363667A1 (en) * | 2018-07-17 | 2022-11-17 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| CA3108099A1 (en) * | 2018-07-31 | 2020-02-06 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020043271A1 (en) | 2018-08-28 | 2020-03-05 | F. Hoffmann-La Roche Ag | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease |
| WO2020048583A1 (en) * | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| JP7367004B2 (ja) * | 2018-09-06 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のピラゾロビリジン化合物 |
| WO2020048595A1 (en) * | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| EP3847165A1 (en) * | 2018-09-07 | 2021-07-14 | F. Hoffmann-La Roche AG | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
| US20220112187A1 (en) * | 2018-09-11 | 2022-04-14 | Hoffmann-La Roche Inc. | Pyrazolopyridine amine compounds for the treatment of autoimmune disease |
| EP3623369B1 (en) | 2018-09-12 | 2023-10-25 | F. Hoffmann-La Roche AG | Novel morpholinyl amine compounds for the treatment of autoimmune disease |
| US20210395239A1 (en) * | 2018-09-27 | 2021-12-23 | Hoffmann-La Roche Inc. | Heterocyclyl compounds for the treatment of autoimmune disease |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| CN109516925B (zh) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | 一种谷氨酸-1-甲酯-5-叔丁酯的合成方法 |
| JP2022506790A (ja) * | 2018-11-09 | 2022-01-17 | エフ．ホフマン－ラ ロシュ アーゲー | 全身性エリテマトーデスを処置するためのＴＬＲ７～９アンタゴニストとしての、５－［６－［［３－（４，５，６，７－テトラヒドロピラゾロ［４，３－ｃ］ピリジン－１－イル）アゼチジン－１－イル］メチル］モルホリン－４－イル］キノリン－８－カルボニトリル誘導体及び類似化合物 |
| CN109369571A (zh) * | 2018-12-04 | 2019-02-22 | 无锡市赛乐新材料科技有限公司 | 一种含氟取代的7-溴-4-醛基苯并噻二唑及其合成方法 |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| MX2021009439A (es) | 2019-02-07 | 2021-11-12 | Beigene Ltd | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| AU2020250468A1 (en) * | 2019-03-29 | 2021-11-04 | Kinki University | Use of T-type calcium channel blocker for treating pruritus |
| SG11202110401WA (en) * | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN112094224B (zh) * | 2019-06-18 | 2022-08-26 | 浙江医药股份有限公司新昌制药厂 | 一种带保护基的3-取代-5-氨基哌啶的制备方法 |
| CN114206872A (zh) | 2019-08-02 | 2022-03-18 | 百济神州有限公司 | 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| JP2022546863A (ja) * | 2019-09-10 | 2022-11-09 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規キノリン化合物 |
| WO2021052892A1 (en) | 2019-09-16 | 2021-03-25 | F. Hoffmann-La Roche Ag | Piperidinyl amine compounds for the treatment of autoimmune disease |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| US12590298B2 (en) | 2019-10-18 | 2026-03-31 | The Regents Of The University Of California | Ex vivo tumor angiogenesis model |
| KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| WO2021094301A1 (en) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| JP2023502087A (ja) * | 2019-11-19 | 2023-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| JP7649306B2 (ja) * | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| BR112022009856A2 (pt) * | 2019-11-26 | 2022-08-02 | Hoffmann La Roche | Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune |
| CR20220236A (es) | 2019-11-28 | 2022-10-03 | Bayer Pharma AG | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune |
| US12421229B2 (en) | 2019-12-03 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| BR112022012130A2 (pt) | 2019-12-18 | 2022-08-30 | Intervet Int Bv | Compostos antelmínticos compreendendo uma estrutura azaindólica |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| BR112022012179A2 (pt) | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| TW202200139A (zh) * | 2020-05-14 | 2022-01-01 | 德商馬克專利公司 | 用於治療冠狀病毒感染之tlr7/8拮抗劑 |
| CA3182616A1 (en) * | 2020-06-15 | 2021-12-23 | Lukas Shinji OKITSU | Tlr7/8 antagonists and uses thereof |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2022028389A1 (zh) * | 2020-08-03 | 2022-02-10 | 江苏恒瑞医药股份有限公司 | 稠三环类衍生物、其制备方法及其在医药上的应用 |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
| CN116490506B (zh) | 2020-11-26 | 2024-12-13 | 江苏恒瑞医药股份有限公司 | 稠合三环化合物、其制备方法及其在医药上的应用 |
| KR102513463B1 (ko) | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN115160296B (zh) * | 2022-08-08 | 2024-05-28 | 西安市第五医院 | 一种n-取代喹啉-4-胺类化合物及其制备、药物组合物和应用 |
| CN115650881B (zh) * | 2022-09-06 | 2025-01-17 | 浙江医药股份有限公司新昌制药厂 | 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法 |
| CN120603821A (zh) | 2023-01-18 | 2025-09-05 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025214612A1 (en) | 2023-04-14 | 2025-10-16 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025261608A1 (en) | 2023-06-29 | 2025-12-26 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2026002399A1 (en) | 2023-07-07 | 2026-01-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2026017247A1 (en) | 2023-07-28 | 2026-01-22 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| KR20260049277A (ko) | 2023-08-09 | 2026-04-13 | 메르크 파텐트 게엠베하 | 5-((3R,55)-3-아미노-5-트리플루오로메틸-피페리딘-1-일)-퀴놀린-8-카르보니트릴HCl 결정형 A1 |
| IL326278A (en) | 2023-08-09 | 2026-04-01 | Merck Patent Gmbh | Crystalline form H1 of 5-((3R,5S)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate |
| WO2025032197A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025252556A1 (en) | 2024-06-05 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4667451A1 (en) | 2024-06-21 | 2025-12-24 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4692056A1 (en) | 2024-08-06 | 2026-02-11 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4691242A1 (en) | 2024-08-06 | 2026-02-11 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4703353A1 (en) | 2024-09-03 | 2026-03-04 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1020252A (en) * | 1911-04-26 | 1912-03-12 | Arthur H Bell | Brooder. |
| US1016829A (en) * | 1911-05-19 | 1912-02-06 | Abraham Hurwitz | Device for setting pallet-jewels. |
| US1227293A (en) * | 1914-04-10 | 1917-05-22 | Charles H Morison | Safety-catch for cuff-buttons. |
| US1271680A (en) * | 1918-01-15 | 1918-07-09 | Emanuel W Dunn | Heater. |
| US1367747A (en) * | 1919-05-07 | 1921-02-08 | George B Keplinger | Bath-brush |
| DE812911C (de) | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| MXPA04004443A (es) | 2001-11-14 | 2004-08-11 | Merck Patent Gmbh | Derivados de pirazol. |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| PL375042A1 (en) | 2002-08-12 | 2005-11-14 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| BR0316164A (pt) | 2002-11-12 | 2005-09-27 | Pfizer Prod Inc | Derivados de quinolina |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20070225308A1 (en) | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| EP1756101A2 (en) | 2004-05-17 | 2007-02-28 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| CN101023083A (zh) * | 2004-07-23 | 2007-08-22 | 田边制药株式会社 | 含氮的稠合双环化合物 |
| JP2006056882A (ja) | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物 |
| WO2006009245A1 (ja) | 2004-07-23 | 2006-01-26 | Tanabe Seiyaku Co., Ltd. | 含窒素縮合二環式化合物 |
| US20090264415A2 (en) * | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| CA2659851C (en) * | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| JP2010504367A (ja) | 2006-09-26 | 2010-02-12 | グラクソ グループ リミテッド | 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体 |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| AU2008258871B2 (en) | 2007-06-05 | 2013-08-15 | Sanofi-Aventis | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them |
| EP2285217A4 (en) | 2008-05-12 | 2011-06-08 | Amnestix Inc | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| JP5564045B2 (ja) | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| CN102216299B (zh) * | 2008-12-01 | 2015-02-11 | 默克专利有限公司 | 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物 |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| WO2010097410A1 (en) * | 2009-02-24 | 2010-09-02 | Respiratorius Ab | Novel bronchodilating diazaheteroaryls |
| NO2453895T3 (2) | 2009-07-16 | 2018-10-20 | ||
| US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| SG10202103278TA (en) * | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| ES2670550T3 (es) * | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| EP3080124A1 (en) * | 2013-12-13 | 2016-10-19 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US9938282B2 (en) | 2014-02-05 | 2018-04-10 | Stereokem, Inc. | Expedient synthesis of sitagliptin |
| SG11201607973XA (en) | 2014-03-24 | 2016-11-29 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| PT3134402T (pt) | 2014-04-22 | 2020-07-02 | Hoffmann La Roche | Compostos de 4-amino-imidazoquinolina |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| WO2016071293A2 (en) | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| ES2965044T3 (es) | 2017-07-18 | 2024-04-10 | Merck Patent Gmbh | Antagonistas de TLR7/8 y sus usos |
| CN111511729A (zh) | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CA3108099A1 (en) * | 2018-07-31 | 2020-02-06 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
-
2016
- 2016-12-16 PT PT211729967T patent/PT3889145T/pt unknown
- 2016-12-16 CN CN202110952016.2A patent/CN113603675A/zh active Pending
- 2016-12-16 MX MX2018006637A patent/MX385424B/es unknown
- 2016-12-16 MY MYPI2023001174A patent/MY210123A/en unknown
- 2016-12-16 NZ NZ742476A patent/NZ742476A/en unknown
- 2016-12-16 CA CA3005766A patent/CA3005766A1/en active Pending
- 2016-12-16 JP JP2018531479A patent/JP6882299B2/ja active Active
- 2016-12-16 DK DK21172996.7T patent/DK3889145T3/da active
- 2016-12-16 SI SI201631813T patent/SI3889145T1/sl unknown
- 2016-12-16 FI FIEP21172996.7T patent/FI3889145T3/fi active
- 2016-12-16 LT LTEP21172996.7T patent/LT3889145T/lt unknown
- 2016-12-16 HU HUE21172996A patent/HUE066591T2/hu unknown
- 2016-12-16 MX MX2021006804A patent/MX2021006804A/es unknown
- 2016-12-16 AU AU2016371014A patent/AU2016371014B2/en active Active
- 2016-12-16 US US15/381,406 patent/US10399957B2/en active Active
- 2016-12-16 EP EP21172998.3A patent/EP3889146A1/en active Pending
- 2016-12-16 HR HRP20240355TT patent/HRP20240355T1/hr unknown
- 2016-12-16 WO PCT/US2016/067112 patent/WO2017106607A1/en not_active Ceased
- 2016-12-16 SG SG10202001146PA patent/SG10202001146PA/en unknown
- 2016-12-16 EP EP21172996.7A patent/EP3889145B1/en active Active
- 2016-12-16 MY MYPI2018702111A patent/MY196319A/en unknown
- 2016-12-16 SG SG11201804170RA patent/SG11201804170RA/en unknown
- 2016-12-16 ES ES16840344T patent/ES2883285T3/es active Active
- 2016-12-16 EP EP16840344.2A patent/EP3390389B1/en active Active
- 2016-12-16 PL PL21172996.7T patent/PL3889145T3/pl unknown
- 2016-12-16 KR KR1020257009400A patent/KR20250043596A/ko active Pending
- 2016-12-16 SM SM20240141T patent/SMT202400141T1/it unknown
- 2016-12-16 RS RS20240342A patent/RS65319B1/sr unknown
- 2016-12-16 UA UAA201807881A patent/UA124802C2/uk unknown
- 2016-12-16 CN CN201680081793.1A patent/CN108699032B/zh active Active
- 2016-12-16 KR KR1020187018717A patent/KR102787063B1/ko active Active
- 2016-12-16 ES ES21172996T patent/ES2981114T3/es active Active
- 2016-12-19 TW TW112116054A patent/TWI886474B/zh active
- 2016-12-19 TW TW114116751A patent/TW202547833A/zh unknown
- 2016-12-19 TW TW105142060A patent/TWI736566B/zh active
- 2016-12-19 TW TW110137731A patent/TWI804003B/zh active
-
2018
- 2018-05-17 PH PH12018501068A patent/PH12018501068A1/en unknown
- 2018-05-21 ZA ZA2018/03367A patent/ZA201803367B/en unknown
- 2018-05-31 IL IL279751A patent/IL279751B/en active IP Right Grant
- 2018-05-31 IL IL259751A patent/IL259751B/en active IP Right Grant
- 2018-06-15 CL CL2018001624A patent/CL2018001624A1/es unknown
-
2019
- 2019-07-10 US US16/507,870 patent/US10544122B2/en active Active
- 2019-11-26 US US16/696,503 patent/US10696649B2/en active Active
-
2020
- 2020-04-28 US US15/929,348 patent/US10947213B1/en active Active
- 2020-12-19 US US17/128,021 patent/US11629134B2/en active Active
- 2020-12-24 IL IL279752A patent/IL279752B2/en unknown
- 2020-12-24 IL IL279751A patent/IL279751A/en active IP Right Grant
-
2021
- 2021-02-10 JP JP2021019843A patent/JP7317878B2/ja active Active
- 2021-08-17 AU AU2021218041A patent/AU2021218041B2/en active Active
-
2023
- 2023-03-06 US US18/179,211 patent/US20230303514A1/en not_active Abandoned
- 2023-07-19 JP JP2023117597A patent/JP7829523B2/ja active Active
- 2023-12-18 AU AU2023285714A patent/AU2023285714A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/923,917 patent/US20250059157A1/en active Pending
-
2025
- 2025-11-20 JP JP2025200942A patent/JP2026026116A/ja active Pending
- 2025-11-28 AU AU2025271466A patent/AU2025271466A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537501A5 (2) | ||
| JP2020537671A5 (2) | ||
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| JP2021533125A5 (2) | ||
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| TWI776994B (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| FI3889145T3 (fi) | 8-syaani-5-piperidinokinoliineja TLR7/8-antagonisteina ja niiden käyttö immunologisten häiriöiden hoitoon | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2017524733A5 (2) | ||
| JP2017530959A5 (2) | ||
| JP2015518903A5 (2) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2017509586A5 (2) | ||
| JP2017538689A5 (2) | ||
| JP2018536634A5 (2) | ||
| JP2020517611A5 (2) | ||
| JP2015514060A5 (2) | ||
| JP2014533281A5 (2) | ||
| JP2022515406A5 (2) | ||
| JP2017514910A5 (2) | ||
| JP2017509689A5 (2) | ||
| JP2017502092A5 (2) | ||
| JP2016529306A5 (2) | ||
| HRP20171763T1 (hr) | Derivati piridin-4-ila |